Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Inovio's (INO) DNA Technology Platform Further Validated with Latest Qtr. Results - StifelNovember 9, 2015 2:46 PM Inovio Pharma (INO) Swings to Q3 ProfitNovember 9, 2015 6:28 AM Inovio’s INO-3112 Shows Robust Immune Responses in Patients With Head & Neck CancerNovember 5, 2015 8:01 AM